Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...

Piper Sandler analyst Christopher Raymond maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched ... Vertex is rated Zacks Rank #3 (Hold). The chart below shows the evolution of the company's forward 12-month consensus EPS ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

FDA Approves First Non-Opioid Pain Pill, As Medical Marijuana Remains A Proven Alternative For Relief FDA approves non-opioid pain reliever, suzetrigine, by Vertex Pharmaceuticals to mitigate ...

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $467.00.

Below is a chart showing VRTX's trailing twelve month trading history, with the $470 strike highlighted in orange: Akamai Technologies Inc (Symbol: AKAM) options are showing a volume of 14,642 ...

Below is a chart showing VRTX's trailing twelve month trading history, with the $450.00 strike highlighted in red: Considering the fact that the $450.00 strike represents an approximate 3% premium ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...